Group segmental analysis


  2013   2012      
For the year ended 30 June 2013
R’million
 
R’million
 
R’million
  % of total   Change  
REVENUE FROM CONTINUING OPERATIONS                    
South Africa^ 7 376,8   35   6 159,9   38   20%  
Asia Pacific 7 590,5   37   6 021,0   37   26%  
International @ 3 726,1   18   2 522,9   15   48%  
Sub-Saharan Africa 2 081,5   10   1 651,7   10   26%  
Total gross revenue 20 774,9   100   16 355,5   100   27%  
   Adjustment* (1 466,9)       (1 099,7)          
Total revenue 19 308,0       15 255,8          
OPERATING PROFIT BEFORE AMORTISATION FROM CONTINUING OPERATIONS                    
Adjusted for specific non-trading items ("EBITA")                    
South Africa 1 965,3   35   1 768,4   40   11%  
   Operating profit# 1 867,5       1 616,2       16%  
   Amortisation of intangible assets 60,5       66,8          
   Transaction costs 31,3                
   Restructuring costs       3,4          
   Impairment of assets 6,0       82,0          
Asia Pacific 1 894,0   34   1 460,2   33   30%  
   Operating profit# 1 608,2       1 291,6       25%  
   Amortisation of intangible assets 128,0       100,2          
   Transaction costs 6,0                
   Restructuring costs 151,8       68,4          
International 1 488,7   27   938,5   21   59%  
   Operating profit# 1 321,7       790,9       67%  
   Amortisation of intangible assets 60,8       41,1          
   Settlement of product litigation 43,0                
   Impairment of assets 63,2       106,5          
Sub-Saharan Africa 252,3   4   247,9   6   2%  
   Operating profit# 245,9       241,9       2%  
   Amortisation of intangible assets 6,4       4,2          
   Restructuring costs       1,7          
   Impairment of assets       0,1          
Total EBITA 5 600,3   100   4 415,0   100   27%  
ENTITY WIDE DISCLOSURE – REVENUE FROM CONTINUING OPERATIONS                    
Analysis of revenue in accordance with customer geography                    
South Africa – pharmaceutical 6 201,9   30   5 161,7   32   20%  
South Africa – consumer 1 175,0   6   998,2   6   18%  
Asia Pacific 7 697,6   37   6 088,8   37   26%  
Sub-Saharan Africa 2 123,7   10   1 651,7   10   29%  
Latin America 1 567,3   7   1 023,7   6   53%  
Rest of the world 2 009,5   10   1 431,4   9   40%  
Total gross revenue 20 774,9   100   16 355,5   100   27%  
Adjustment* (1 466,9)       (1 099,7)          
Total revenue 19 308,0       15 255,8       27%  

^ Excludes intersegment revenue of R43,0 million (2012: R29,6 million).
@ Excludes intersegment revenue of R1 201,5 million (2012: R432,3 million).
* The profit share from the Aspen GSK Healthcare for Africa collaboration has been disclosed as revenue in the statement of comprehensive income. For segmental purposes the total revenue for the Aspen GSK Healthcare for Africa collaboration has been included to provide enhanced revenue visibility in this territory.
# The aggregate segmental operating profit total of R5 043,3 million (2012: R3 940,6 million) agrees to the statement of comprehensive income.